MDxHealth, Plus Diagnostics to Co-promote Epigenetic Prostate Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – MDxHealth and Plus Diagnostics today announced a co-promotional deal covering MDxHealth's epigenetic test for prostate cancer in the US.

Plus Diagnostics will build awareness for MDx Health's ConfirmMDx test through its national network of urologists. Financial and other terms of the deal were not disclosed.

"The national reach afforded by Plus Diagnostics provides a direct channel to the urology community and will aid in meeting the growing demand for our test," MDxHealth CEO Jan Groen said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.